PsiOxus to Present Positive Biomarker Data at ESMO 2021 Demonstrating the Potential of Their Novel Tumor-Selective T SIGn® vector, NG-350A, to Re-Engineer Advanced Cancers

OXFORD, UK, 15 September 2021: PsiOxus Therapeutics, Ltd. (PsiOxus), a tumor re-engineering company, today announced that they will present key safety and translational data from their first-in-human phase 1 FORTITUDE clinical study at the European Society for Medical Oncology (ESMO) Congress 2021 this week.  Data from the completed monotherapy dose-escalation part of the FORTITUDE study, initiated in 2019 to assess the safety and tolerability of the NG-350A T-SIGn® vector, will be presented on 16 September 2021, with the poster available in on our website shortly afterwards.

  • Key data from the first-in-human FORTITUDE trial shows that a single cycle of intravenous (IV) NG‑350A drives dose-dependent increases in specific inflammatory biomarkers, consistent with the mechanism of the encoded anti-CD40 agonist.
  • IV dosing of NG-350A led to elevations in IL-12, IFNγ and IL-17 that were higher and sustained for longer than those reported for systemic CD40 agonists.
  • NG-350A monotherapy was well-tolerated and dose exploration will continue in combination with a PD-1 inhibitor.

Download Press Release Here View ESMO 2021 Poster Here